|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/28/20 Geron Corp 10-Q 3/31/20 48:5.8M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 725K
2: EX-10.1 Material Contract HTML 56K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
28: R1 Document and Entity Information HTML 71K
42: R2 Condensed Balance Sheets HTML 92K
36: R3 Condensed Statements of Operations HTML 45K
17: R4 Condensed Statements of Comprehensive Loss HTML 27K
29: R5 Condensed Statements of Stockholders' Equity HTML 55K
43: R6 Condensed Statements of Stockholders' Equity HTML 18K
(Parenthetical)
37: R7 Condensed Statements of Cash Flows HTML 75K
18: R8 Summary of Significant Accounting Policies HTML 97K
27: R9 Fair Value Measurements HTML 420K
14: R10 Former Collaboration Agreement HTML 21K
25: R11 Contingencies and Uncertainties HTML 29K
41: R12 Operating Leases HTML 41K
35: R13 Stockholders' Equity HTML 21K
13: R14 Subsequent Events HTML 21K
24: R15 Summary of Significant Accounting Policies HTML 127K
(Policies)
40: R16 Summary of Significant Accounting Policies HTML 64K
(Tables)
34: R17 Fair Value Measurements (Tables) HTML 416K
15: R18 Operating Leases (Tables) HTML 35K
23: R19 Summary of Significant Accounting Policies - HTML 21K
Anti-Dilutive Shares (Details)
47: R20 Summary of Significant Accounting Policies - HTML 18K
Research and Development (Details)
31: R21 Summary of Significant Accounting Policies - HTML 17K
Useful Lives of Assets (Details)
20: R22 Summary of Significant Accounting Policies - Stock HTML 24K
Based Compensation (Details)
22: R23 Summary of Significant Accounting Policies - Stock HTML 51K
Options and Employee Stock Purchase Plan (Details)
45: R24 Fair Value Measurements - Security Type (Details) HTML 64K
30: R25 Fair Value Measurements - Securities With HTML 39K
Unrealized Losses (Details)
19: R26 Fair Value Measurements - Recurring Basis HTML 40K
(Details)
21: R27 Fair Value Measurements - Equity Investment HTML 37K
(Details)
44: R28 Former Collaboration Agreement (Details) HTML 35K
32: R29 Operating Leases (Details) HTML 45K
33: R30 Operating Leases - Future Non-Cancellable Lease HTML 35K
Payments (Details)
38: R31 Stockholders' Equity - at Market Issuance Sales HTML 30K
Agreement (Details)
26: R32 Stockholders' Equity - 2018 Inducement Award Plan HTML 20K
(Details)
16: R33 Subsequent Events (Details) HTML 51K
48: XML IDEA XML File -- Filing Summary XML 78K
39: EXCEL IDEA Workbook of Financial Reports XLSX 54K
7: EX-101.INS XBRL Instance -- gern-20200331 XML 1.56M
9: EX-101.CAL XBRL Calculations -- gern-20200331_cal XML 115K
10: EX-101.DEF XBRL Definitions -- gern-20200331_def XML 271K
11: EX-101.LAB XBRL Labels -- gern-20200331_lab XML 725K
12: EX-101.PRE XBRL Presentations -- gern-20200331_pre XML 490K
8: EX-101.SCH XBRL Schema -- gern-20200331 XSD 94K
46: ZIP XBRL Zipped Folder -- 0001564590-20-027307-xbrl Zip 105K
EXHIBIT 31.1
CERTIFICATION PURSUANT TO
FORM OF RULE 13A-14(A)
AS ADOPTED PURSUANT TO
SECTION 302(A) OF THE SARBANES-OXLEY ACT OF 2002
I, John A. Scarlett, M.D., certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Geron Corporation; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: May 28, 2020 |
|
|
|
|
|
|
|
/s/ JOHN A. SCARLETT |
|
|
|
JOHN A. SCARLETT, M.D. |
|
|
|
President and Chief Executive Officer |
|
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/28/20 | 8-K | ||
| For Period end: | 3/31/20 | 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/22 Geron Corp. 424B5 1:909K ActiveDisclosure/FA 3/29/22 Geron Corp. 424B5 1:910K ActiveDisclosure/FA 11/06/20 Geron Corp. 424B5 1:101K DG3/FA 9/04/20 Geron Corp. S-3 7:965K DG3/FA 8/06/20 Geron Corp. 10-Q 6/30/20 48:7.4M ActiveDisclosure/FA |